肝素诱导的高血症,LMWH可以引起高血症吗? 一个系统的审查
Gedion Yilma Amdetsion1,2, Aron Gudeta1, Guy Lumley2
1Internal Medicine Division Addis Ababa University Addis Ababa Ethiopia.
EJHaem
|November 29, 2023
概括
低分子量肝素 (LMWH) 的使用没有显著增加患者的水平. 这次系统性审查没有发现强有力的证据将LMWH与高血症联系在一起,这表明它是如此.
科学领域:
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内部医学 内部医学
背景情况:
- 高血症,定义为血>5.0mEq/L,与不良结果有关,在住院患者中很常见.
- 药物诱导的高胆固醇血症是一个重大问题,与肝素有关,虽然比其他副作用更少被认可.
- 怀疑未分离的氨酸 (UFH) 和低分子量氨酸 (LMWH) 都会通过阿尔多抑制和血管激素II受体调节引起高血症.
研究的目的:
- 系统地审查关于肝素,特别是LMWH与高血症发生率之间的关系的现有文献.
- 评估证据支持LMWH是高血的原因,并探索潜在的潜在机制.
主要方法:
- 进行了一项系统性审查,分析了13项研究.
- 该审查包括总共1407名接受LMWH.患者.
- 评估了与LMWH使用相关的水平和高血症发病率的数据.
主要成果:
- 关于LMWH诱导的高血症,发现缺乏高质量的证据.
- 在使用LMWH时,没有观察到血液水平的统计显著增加.
- LMWH没有证明与高胆固醇血发病率的剂量反应关系,并且潜在的机制仍然是不确定的.
结论:
- 目前的证据表明,LMWH不太可能是高血症的主要原因.
- 建议在处方LMWH时谨慎使用,特别是在已经存在高水平的患者中.
- 需要进一步进行高质量的研究,以最终阐明任何潜在的联系和机制.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
711
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
711
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
582
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
582
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.0K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.0K
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
01:22Heart Failure Drugs: Diuretics
396
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
396